Option chain shows key data for vTv Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) Stock, Option Chain

vTv Therapeutics

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.

Analyst,Works,On,Personal,Computer,Showing,Business,Analytics,Dashboard,With

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BASE

PVLA

VTVT

This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Biotech

Health Care

Movers

General

vTv Therapeutics&#39; Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month timeline to accelerate key studies.

FDA Lifts Clinical Hold On vTv Therapeutics&#39; Phase 3 Diabetes Trial, Stock Surges

Wall Street

Eurozone

Commodities

Intraday Update

CGTX

LIPO

NLSP

VERO

VTYX

Dow Edges Lower; Ventyx Biosciences Shares Plummet

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics Inc

Press Releases

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Earnings

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Management

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Adicet Bio

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Avalo Therapeutics

BeyondSpring

Cabaletta Bio

Cibus

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

CytomX Therapeutics

Citius Oncology

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Forte Biosciences

Gain Therapeutics

ImmuCell

Immuneering Corporation - Class A Common Stock

Immuneering

Kronos Bio

MAIA Biotechnology

Metagenomi

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PMV Pharma

Quince Therapeutics

Repare Therapeutics

Serina Therapeutics

Skye Bioscience

Sutro Biopharma

HC Wainwright & Co.

Alliance Global Partners

Northland Capital Markets

Comments

vTv Therapeutics

vTv Therapeutics (VTVT) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell